The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside [Corrigendum]

This article refers to:

The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside

Rovero P, Malgapo DMH, Sparavigna A, Beilin G, Wong V, Lao MP. Clin Cosmet Investig Dermatol. 2022;15:2693–2703.

The authors have advised that there is an error in the Study characteristics for Face serum (ISPE, 2022) in Table 2 on page 2698. The correct Table 2 is as follows.

Table 2 Results of Instrumental and Subjective Evaluations of SA1-III Face Cream and Face Serum

Product	Face Cream (ISPE, 2018)^25	Face Serum (ISPE, 2022)^26
Study characteristics	Included 20 female volunteers aged 40 to 70 years (average age of 60.0 years) All volunteers applied KP1 face cream twice daily for 4 weeks)	Included 20 female and 10 male volunteers All volunteers applied KP1 face serum
Results (baseline vs end of study)
Skin hydration (cu)	52.2 ± 5.3 vs 74.7 ± 8.2 (Δ22.5; 43.1%; p<0.0001)	52.5 ± 9.6 vs 69.3 ± 11.0 (Δ16.8; 32.0%; p<0.0001)
Skin deep hydration (%)	NR	49.9 ± 5.1 vs 53.2 ± 4.0 (3.3; p<0.01)
Skin extensibility (mm)	0.230 ± 0.056 vs 0.197 ± 0.058 (Δ−0.033; −14.3%; p<0.0001)	0.296 ± 0.084 vs 0.212 ± 0.084 (Δ−0.084; −28.4%; p<0.0001)
Gross elasticity	0.591 ± 0.066 vs 0.625 ± 0.063 (Δ0.034; 5.8%; p<0.0001)	0.668 ± 0.110 vs 0.726 ± 0.103 (Δ0.058; 8.7%; p<0.0001)
Skin echogenicity/density (%)	31.54 ± 6.04 vs 33.77 ± 5.22 (2.23; p<0.001)	30.15 ± 6.53 vs 32.82 ± 6.81 (Δ2.67; p<0.0001)
Average skin roughness (μm)	66.4 ± 4.4 vs 58.8 ±15.3 (Δ−8.6; −13.0%; p<0.01)	46.2 ± 12.2 vs 40.0 ± 8.8 (Δ−6.2; −13.4%; p<0.001)
Average maximum roughness (μm)	849 ± 145 vs 763 ± 193 (−86; −10.1%; p<0.001)	540.1 ± 123.2 vs 462.7 ± 114.4 (−77.4; −14.3%; p<0.001)

The authors apologise for this error.